ClinPGx Blog (Page 48)

Sign in Subscribe

More issues

PharmGKB has an opening for a scientific curator

PharmGKB is looking to fill a Curator position in the Department of Genetics at Stanford University. We are specifically looking for someone with a clinical or pharmacology background to add to the curation team. This position works with a group of curators to collect and analyze information from the scientific

Genetic contribution of response to opioids

Opioids are commonly prescribed for pain relief, yet many individuals suffer adverse side effects such as nausea, dizziness and sedation. A study published in this month's Anesthesiology set out to establish the relative contribution of genetic and environmental factors in opioid response. 114 monozygotic and dizygotic twin pairs

Helix Group & PharmGKB Retreat

Much fun and team-building was had at the Stanford Helix Group & PharmGKB retreat in San Diego last week - including sea kayaking, insightful talks and a lively discussion with guest speaker Philip Bourne.

Curators' Favorite Papers

The current Curators' Favorite Papers are about pharmacogenomics of antidepressant drugs. Narasimhan and Lohoff review recent findings on the pharmacogenetics of antidepressant drugs and discuss possible future clinical implementations [PMID: 22380000]. The study by de Klerk et al. investigates the association of ABCB1 variants with adverse effects of antidepressants

Metformin Pharmacogenomics

Metformin is a first line therapy for type 2 diabetes, and is one of the most commonly prescribed drugs worldwide. We have recently written a Metformin Pathways Summary that is published in Journal Pharmacogenetics and Genomics. Metformin effectively lowers both basal and postprandial plasma glucose. However, the glycemic response to

New haplotypes available on PharmGKB

Haplotypes for the UGT1A3, CYP2F1 and CHRNA5 genes are now available on www.pharmgkb.org View a list of all the genes with haplotypes available on PharmGKB.

CYP2C19 and clopidogrel therapy CPIC guideline endorsed by the ASHP

The American Society of Health-System Pharmacists (ASHP) has endorsed the CPIC guidelines for CYP2C19 genotype and clopidogrel therapy, published in Clinical Pharmacology and Therapeutics. In their report, they highlight that the guidelines address an important need for information on the clinical application of pharmacogenomic testing and appreciate that the

Curators' Favorite Papers

The current Curators' Favorite Papers are about rare variants, which are part of the genetic diversity within and among populations. Keinan and Clark explain how the recent explosive human population growth has resulted in an excess of rare genetic variants [PMID: 22582263]. The article by Nelson et al. focuses

FDA approves new ERBB2 targeted drug

The FDA approved a new drug for HER2 (ERBB2) positive breast cancer (June 8, 2012). Pertuzumab (Perjeta) is an antibody that targets a different epitope than trastuzumab (Herceptin), the first HER2 targeted antibody drug. The two drugs can therefore be combined to improve efficacy, and this was shown quite successfully

New PGRN Featured Project and PI for the Month of June

The PGRN website is featuring a new project and investigator of the month from the PPII (Pharmacogenetics of Phase II Drug Metabolizing Enzymes) group. For detailed information, please visit the PGRN website.